950130 — Access Bio Share Price
Last trade - 00:00- KR₩452bn
- KR₩162bn
- $267.08m
- 43
- 79
- 13
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.72 | ||
| Price to Tang. Book | 0.72 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.23 | ||
| EV to EBITDA | 3.86 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.6% | ||
| Return on Equity | -0.52% | ||
| Operating Margin | 6.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 36.94 | 103.21 | 441.37 | 800.23 | 267.08 | n/a | n/a | 48.83% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +262.73 | +59.05 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Access Bio, Inc. is engaged in research, development and manufacturing of in vitro rapid diagnostic tests, biosensors and molecular diagnostic products. Its product list includes covid-19 detection kits, rapid diagnostic tests, analyzers and molecular diagnostics. Its covid-19 detection kits include CareStart COVID-19 Antigen Home Test, CareStart COVID-19 Antigen, CareStart COVID-19 MDx RT-PCR, CareStart COVID-19 lgM/lgG and CareStart EZ COVID-19 lgM/lgG. Its rapid diagnostic tests include CareStart EZ HIV, CareStart Flu A&B Plus+, CareStart G6PD RDT, CareStart Malaria RDT, CareStart Dengue RDT, care US HIV 1/2 and care US Syphilis. The analyzers include care SURE Analyzer 100, care SURE A1c Cartridge, care SURE ACR Cartridge, care SURE CRP Cartridge, care START S1 Analyzer and care START G6PD Biosensor. The molecular diagnostics include care GENE HPV Screening kit-H, care GENE Zika Virus RT-PCR kit, care GENE STD detection kit, care GENE Dengue Virus genotyping kit and others.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 27th, 2002
- Public Since
- May 30th, 2013
- No. of Shareholders
- 43,079
- No. of Employees
- 63
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 70,177,696
- Address
- 65 CLYDE ROAD, SUITE A, SOMERSET, 08873
- Web
- https://accessbio.net/
- Phone
- +1 7328734040
- Auditors
- Woori Accountants
Upcoming Events for 950130
Similar to 950130
Aligned Genetics
Korea Exchange - KOSDAQ
Angel Robotics Co
Korea Exchange - KOSDAQ
Asta Co
Korea Exchange - KOSDAQ
Biodyne Co
Korea Exchange - KOSDAQ
Bistos Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 19:00 UTC, shares in Access Bio are trading at KR₩6,440. This share price information is delayed by 15 minutes.
Shares in Access Bio last closed at KR₩6,440 and the price had moved by -36.57% over the past 365 days. In terms of relative price strength the Access Bio share price has underperformed the FTSE Developed Asia Pacific Index by -33.79% over the past year.
There is no consensus recommendation for this security.
Access Bio does not currently pay a dividend.
Access Bio does not currently pay a dividend.
Access Bio does not currently pay a dividend.
To buy shares in Access Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩6,440, shares in Access Bio had a market capitalisation of KR₩452bn.
Here are the trading details for Access Bio:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 950130
Based on an overall assessment of its quality, value and momentum Access Bio is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Access Bio. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -32.48%.
As of the last closing price of KR₩6,440, shares in Access Bio were trading -25.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Access Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩6,440.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Access Bio's directors